Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
180
resultados
Última actualización
11/05/2025 [07:16:00]
Resultados 125 a 150 de 180
Resumen de: WO2025064641A1
Embodiments are directed to dihydroisoquinolinone (Dhq) monomers and synthetic compounds comprises at least Dhq monomer having the structure (I). In such embodiments, X is selected from C and N and each R1 and R2 are independently selected from H, O, phenyl, allyl, alkenyl, carbonyl, and a combination thereof. In some embodiments, the synthetic compounds can bind to a spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or to fentanyl.
Resumen de: WO2025064752A1
The present invention includes a monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that binds to the S2 domain of the SARS-CoV-2 Spike protein.
Resumen de: WO2025062057A1
The present invention relates to 5-fluorouracil (5-FU) for use thereof as an antiviral, alone or in combination with peptides that inhibit binding between nsp10 and nsp14 and between nsp10 and nsp16, acting against viruses of the family Coronaviridae, preferably SARS-CoV-2.
Resumen de: US2025099424A1
The invention relates to compounds of Formula I″wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
Resumen de: US2025099573A1
Provided are a polypeptide antigen derived from the S protein of SARS-CoV-2, a polypeptide vaccine containing the same, and applications thereof. The amino acid sequence of the polypeptide antigen provided by the present disclosure is as shown in any one of SEQ ID NOs: 1-116.
Resumen de: US2025099576A1
Provided herein are 3′ and 5′ UTRs that provide an amount, duration, or both of protein expression from a recombinant RNA. Compositions of matter, methods, or uses of said 3′ and 5′ UTRs are provided. Provided herein are RNA segments that encode a SARS-CoV-2 omicron spike protein, which provide for omicron-strain-specific immunogenic compositions. Compositions of matter, methods, or uses of said RNA segments that encode a SARS-CoV-2 omicron spike protein are provided.
Resumen de: US2025099474A1
The present invention provides a pharmaceutical composition containing a coronavirus 3CL protease inhibitor for treating novel coronavirus infections (COVID-19).A pharmaceutical composition for treating novel coronavirus infections (COVID-19) is provided, the composition containing, as an active ingredient, a complex that contains:a compound represented by Formula (I):andfumaric acid.
Resumen de: GB2634002A
A method for producing a SARS-CoV-2 virus-like particle-based protein subunit vaccine. The method comprises creating a fusion protein by combining a DNA sequence encoding an iLOV protein with a DNA sequence encoding a peptide linker and a cleavage site for enterokinase protease and a DNA sequence encoding a Receptor Binding Domain (RBD) of the SARS-CoV-2 viral spike protein. The RBD protein is attached to a “Spy Tag” peptide. The peptide linker cleavage site DNA sequence is between the iLOV protein DNA sequence and either the SARS-CoV-2 viral protein DNA sequence or the “Spy Tag” peptide DNA sequence. The DNA sequence encoding the fusion protein is introduced into a P. pastoris host to form transformants. At least one optimal recombinant is identified from the transformants using fluorescence to detect optimal expression levels of the SARS-CoV-2 viral protein. The SARS-CoV-2 viral protein is isolated from the fusion protein by cleaving the iLOV protein and linker sequences from the target protein. The RBD sequence can be mutated to represent RBD variants or homologous sequences or improve expression and alter its glycosylation pattern. The RBD sequence can belong to any virus within the coronavirus family.
Resumen de: ZA202309295B
A method to produce immunoglobulin preparations against viral infection in humans spreading via respiratory route is provided. The method comprises the steps of immunizing dairy cows during a third trimester of at least a first gestation period with antigen proteins derived from at least one virus strain, collecting hyperimmune bovine colostrum comprising immunoglobulins effective against the antigen protein of various strains of the virus, preparing whey from the colostrum, isolating the immunoglobulin molecules from the whey, and preparing an immunoglobulin preparation for use as an intranasal treatment. One aspect of the invention is to produce SARS-CoV-2 spike protein specific hyperimmune bovine colostrum comprising a high concentration of anti-SARS-CoV-2 antibodies. An intranasal delivery system for diminishing risk of SARS-CoV-2 infections in humans is provided.
Resumen de: ZA202309817B
This invention relates to methods of diagnosing COVID-19 disease, preferably post-acute COVID-19 syndrome, in a subject using a fluorescent or microscopy detection method to detect persistent anomalous (amyloid) clotlets in the sample, wherein the presence of persistent anomalous (or amyloid) clotlets in the sample, particularly clotlets that are resistant to fibrinolysis, is indicative of either acute COVID-19 disease or post-acute COVID-19 syndrome in the subject. The invention also relates to diagnostic kits for diagnosing acute COVID-19 disease, in particular post-acute COVID-19 syndrome, in a subject based on the methods disclosed.
Resumen de: WO2023223189A1
The present invention relates to the use of glycerophosphoinositol (GPI) in preventing and treating COVID-19 infections, and an environmentally sustainable method for obtaining it. In particular, the present invention is directed to a process for preparing glycerophosphoinositol from crude or partially purified phospholipid mixtures, comprising the following steps in sequence: a) hydrolysis of a crude or partially purified phospholipid mixture by treatment with PLA1 and PLA2 enzymes; b) microfiltration of the mixture from step a) and subsequent ultrafiltration and nanofiltration of the microfiltrate to give a concentrated aqueous fraction of reaction products; c) electrodialysis of the aqueous fraction of step b) for separating ionic compounds from neutral compounds; d) ion exchange chromatography. The invention further relates to the use of glycerophosphoinositol in preventing and treating a COVID-19 syndrome.
Resumen de: US2025090657A1
The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.
Resumen de: US2025092016A1
Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.
Resumen de: US2025090557A1
Disclosed herein are methods of using one or more mitochondrial targeted antioxidants, such as mitoquinol or mitoquinone, to prevent, inhibit, and/or treat infections and symptoms caused by infection by a coronavirus, such as SARS-CoV-2.
Resumen de: US2025092029A1
Disclosed herein are compounds of the formulas (I) as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit Mpro proteases. Also provided are methods of administering compounds and compositions provided herein to a patient in need thereof, for example, for the treatment of diseases such as SARS-CoV-2 or a variant thereof.
Resumen de: US2025089707A1
An eco-friendly quarantine composition has a function of killing phospholipid enveloped viruses, The eco-friendly quarantine composition includes: 10 to 40 wt. % of polyoxyethylene lauryl ether, 0.01 to 10 wt. % of polyoxyethylene 2-ethylhexyl ether, 0.01 to 10 wt. % of polyoxyethylene polyoxypropylene alkyl ether, and a balance of solvent, based on the total 100 wt. % of the composition. The eco-friendly quarantine composition may have 100% of SARS-CoV-2 virus removal rate in 1 minute and an effect of killing 100% of highly pathogenic avian influenza virus in 1 to 10 minutes. The composition has low cytotoxicity such that IC50 value (%) for human epithelial keratinocyte cells (HaCaT), human bronchial epithelial cells (BEAS-2B), and human monocyte cells (THP-1) is in a range of 0.003 to 0.0045, and effects of having antibacterial activity against non-pathogenic strains, and pathogenic strains.
Resumen de: US2025090568A1
A method of treating or preventing Alzheimer's disease or related dementias in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Brain gene expression profiles of severe COVID-19 patients show increased expression of several innate immune response genes and genes implicated in Alzheimer's disease pathogenesis. The gene expression signature includes genes involved in inflammation, protein folding/trafficking, complement activation, calcium homeostasis, and amyloid/tau processing. The gene expression signature is correlated with tau pathology, α-synuclein, and demyelination with neuroinflammation being increased in old versus young CoV-2 infected mice.
Resumen de: AU2023326053A1
Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological sample from the subject. Also disclosed herein are methods for treating a subject identified as having a high likelihood of suffering from NP ASC and treating the subject by modulating the level or activity of an NPASC therapeutic target identified herein.
Resumen de: AU2023329395A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.
Resumen de: AU2023333282A1
This disclosure concerns amplification primers, hybridization assay probes, compositions containing such primers and probes, and associated reagents, kits, and methods, that can be used to analyze samples for the presence of SARS-CoV-2, Influenza A virus, Influenza B virus, Respiratory Syncytial Virus A, and/or Respiratory Syncytial Virus B target nucleic acids.
Resumen de: US2025090516A1
Provided is a therapeutic agent for novel coronavirus infection sequelae. The therapeutic agent for novel coronavirus infection sequelae contains an acetylcholine receptor agonist as an active ingredient.
Resumen de: US2025090620A1
Clean version of Abstract A mixture consisting of extracts of green tea, bilberry, pomegranate peel, and black poplar Propolis is produced. Upon revealing the surprising efficacy of the mixture against SARS-CoV-2 virus, the mixture was put into lozenge/chewable tablet form and its activity against the SARS-CoV-2 virus was demonstrated. The invention was developed in the form of a throat lozenge/chewable tablet in order to provide a protective effect around the mouth and throat, which is the first point of entry of the SARS-CoV-2 virus. The effectiveness of the mixture against SARS-CoV-2 virus was tested on VERO E6 cells by in vitro methods. In the experiments lasting 160 hours, the mixture neutralizes the virus by 112% (61% cell viability) at 110 μg/mL concentration and by 35% (82% cell viability) at 70 μg/mL concentration. The combination of herbal extracts with Propolis extract were synergically more effective (−7-fold higher) than that of individual extract.
Resumen de: US2025090653A1
The present disclosure relates to vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use. The vaccine formulations further comprise DNA vectors encoding SARS-Cov-2 spike protein variants comprising single amino acid substitutions and polynucleotides which encode an adjuvant, further wherein the vaccine is formulated with a proteolipid vesicle or fusogenic membrane protein.
Resumen de: US2025090522A1
Certain embodiments described herein include methods and formulations for treating or preventing symptoms and conditions associated with coronavirus disease (e.g., COVID-19). The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
Nº publicación: US2025090656A1 20/03/2025
Solicitante:
INST PASTEUR [FR]
INSTITUT PASTEUR
Resumen de: US2025090656A1
The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.
BOPI
Sede Electrónica
